FY2025 EPS Estimates for Septerna Lowered by HC Wainwright

Septerna, Inc. (NASDAQ:SEPN) – HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for Septerna in a note issued to investors on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($1.53) per share for the year, down from their prior forecast of ($1.45). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna’s Q4 2025 earnings at ($0.16) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.61) EPS and FY2026 earnings at ($1.67) EPS.

Several other brokerages also recently issued reports on SEPN. Jones Trading began coverage on shares of Septerna in a report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Truist Financial began coverage on Septerna in a research note on Monday, December 15th. They set a “buy” rating and a $34.00 price target on the stock. Wall Street Zen cut Septerna from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 10th. Finally, Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $18.00 to $28.00 in a report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.83.

Septerna Price Performance

Shares of NASDAQ:SEPN opened at $26.35 on Thursday. Septerna has a one year low of $4.17 and a one year high of $30.50. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -17.45 and a beta of 3.85. The firm has a 50 day simple moving average of $26.56 and a 200 day simple moving average of $19.60.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The company had revenue of $21.50 million during the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%.

Hedge Funds Weigh In On Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in SEPN. Covestor Ltd lifted its holdings in Septerna by 55.8% in the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after buying an additional 1,296 shares during the period. JPMorgan Chase & Co. raised its position in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares in the last quarter. PharVision Advisers LLC lifted its stake in shares of Septerna by 17.5% in the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Septerna during the 3rd quarter valued at about $36,000. Finally, BNP Paribas Financial Markets grew its stake in Septerna by 88.0% during the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after purchasing an additional 1,945 shares during the period.

Insider Buying and Selling

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the sale, the senior vice president owned 92,911 shares in the company, valued at approximately $1,677,972.66. The trade was a 3.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.30% of the company’s stock.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.